Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in HRAS mutant urothelial carcinoma
NCT02535650Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Nov 2015
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib in urothelial carcinoma (UC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
tipifarnib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02535650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535650.